These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16412255)

  • 1. The association between diabetes related medical costs and glycemic control: a retrospective analysis.
    Oglesby AK; Secnik K; Barron J; Al-Zakwani I; Lage MJ
    Cost Eff Resour Alloc; 2006 Jan; 4():1. PubMed ID: 16412255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis.
    Boye KS; Lage MJ; Thieu VT
    Diabetes Ther; 2022 Feb; 13(2):367-377. PubMed ID: 35129822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases.
    Degli Esposti L; Saragoni S; Buda S; Sturani A; Degli Esposti E
    Clinicoecon Outcomes Res; 2013; 5():193-201. PubMed ID: 23696709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Costs and Factors Associated with Glycemic Control among Patients with Diabetes in the United Arab Emirates.
    Lee SM; Song I; Suh D; Chang C; Suh DC
    J Obes Metab Syndr; 2018 Dec; 27(4):238-247. PubMed ID: 31089569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.
    Boye KS; Bae JP; Thieu VT; Lage MJ
    Diabetes Ther; 2024 Feb; 15(2):395-407. PubMed ID: 38038897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association Between Poor Glycemic Control and Health Care Costs in People With Diabetes: A Population-Based Study.
    Mata-Cases M; Rodríguez-Sánchez B; Mauricio D; Real J; Vlacho B; Franch-Nadal J; Oliva J
    Diabetes Care; 2020 Apr; 43(4):751-758. PubMed ID: 32029636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus.
    Mitchell BD; Eby EL; Lage MJ
    Curr Med Res Opin; 2013 Dec; 29(12):1587-97. PubMed ID: 23886028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002.
    Fox KM; Gerber Pharmd RA; Bolinder B; Chen J; Kumar S
    Clin Ther; 2006 Mar; 28(3):388-95. PubMed ID: 16750453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period.
    Mansour AA; Alibrahim NTY; Alidrisi HA; Alhamza AH; Almomin AM; Zaboon IA; Kadhim MB; Hussein RN; Nwayyir HA; Mohammed AG; Al-Waeli DKJ; Hussein IH;
    Diabetes Metab Syndr; 2020; 14(3):265-272. PubMed ID: 32272433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.
    Durden E; Lenhart G; Lopez-Gonzalez L; Hammer M; Langer J
    J Med Econ; 2016; 19(4):403-13. PubMed ID: 26653068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of glycemic control: A cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China.
    Bi Y; Zhu D; Cheng J; Zhu Y; Xu N; Cui S; Li W; Cheng X; Wang F; Hu Y; Shen S; Weng J
    Clin Ther; 2010 May; 32(5):973-83. PubMed ID: 20685506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.